Research Analysts Set Expectations for Neurocrine Biosciences, Inc.'s Q1 2025 Earnings (NASDAQ:NBIX)

Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) - William Blair issued their Q1 2025 earnings estimates for Neurocrine Biosciences in a research note issued to investors on Tuesday, April 23rd. William Blair analyst M. Minter anticipates that the company will post earnings of $1.28 per share for the quarter. The consensus estimate for Neurocrine Biosciences' current full-year earnings is $4.84 per share. William Blair also issued estimates for Neurocrine Biosciences' Q2 2025 earnings at $1.56 EPS, Q3 2025 earnings at $1.75 EPS and Q4 2025 earnings at $1.99 EPS.

A number of other equities analysts have also recently issued reports on the stock. StockNews.com upgraded shares of Neurocrine Biosciences from a "buy" rating to a "strong-buy" rating in a research report on Thursday, February 8th. Cantor Fitzgerald restated an "overweight" rating and set a $155.00 target price on shares of Neurocrine Biosciences in a research report on Wednesday, April 10th. The Goldman Sachs Group boosted their price objective on shares of Neurocrine Biosciences from $134.00 to $153.00 and gave the company a "buy" rating in a research report on Thursday, January 25th. Wedbush reissued an "outperform" rating and issued a $147.00 price objective on shares of Neurocrine Biosciences in a research report on Wednesday, April 17th. Finally, Citigroup cut their price objective on shares of Neurocrine Biosciences from $141.00 to $140.00 and set a "neutral" rating for the company in a research report on Thursday, February 8th. Six investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Neurocrine Biosciences presently has an average rating of "Moderate Buy" and an average target price of $142.38.

Neurocrine Biosciences Price Performance

NBIX traded down $1.21 during midday trading on Thursday, reaching $137.76. 706,045 shares of the company's stock were exchanged, compared to its average volume of 849,545. The stock has a market capitalization of $13.71 billion, a PE ratio of 57.43 and a beta of 0.25. The business's 50-day moving average price is $136.48 and its 200 day moving average price is $127.62. Neurocrine Biosciences has a 1-year low of $89.04 and a 1-year high of $148.37.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last announced its earnings results on Wednesday, February 7th. The company reported $1.44 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.13 by $0.31. The company had revenue of $515.20 million during the quarter, compared to analysts' expectations of $518.52 million. Neurocrine Biosciences had a net margin of 13.23% and a return on equity of 12.85%. The firm's quarterly revenue was up 25.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.88 earnings per share.

Institutional Trading of Neurocrine Biosciences

Several institutional investors have recently added to or reduced their stakes in the stock. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Neurocrine Biosciences by 42.0% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 63,823 shares of the company's stock valued at $8,802,000 after acquiring an additional 18,884 shares in the last quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund raised its holdings in Neurocrine Biosciences by 9.1% in the first quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 42,023 shares of the company's stock valued at $5,796,000 after acquiring an additional 3,500 shares in the last quarter. Assenagon Asset Management S.A. raised its holdings in Neurocrine Biosciences by 7.0% in the first quarter. Assenagon Asset Management S.A. now owns 337,737 shares of the company's stock valued at $46,581,000 after acquiring an additional 22,177 shares in the last quarter. Covenant Asset Management LLC raised its holdings in Neurocrine Biosciences by 1.9% in the first quarter. Covenant Asset Management LLC now owns 28,306 shares of the company's stock valued at $3,904,000 after acquiring an additional 535 shares in the last quarter. Finally, Louisiana State Employees Retirement System raised its holdings in Neurocrine Biosciences by 3.6% in the first quarter. Louisiana State Employees Retirement System now owns 28,600 shares of the company's stock valued at $3,945,000 after acquiring an additional 1,000 shares in the last quarter. 92.59% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, insider Eric Benevich sold 75,000 shares of the company's stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $139.38, for a total value of $10,453,500.00. Following the completion of the transaction, the insider now directly owns 40,778 shares in the company, valued at $5,683,637.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CEO Kevin Charles Gorman sold 2,707 shares of the company's stock in a transaction on Wednesday, January 31st. The shares were sold at an average price of $140.69, for a total value of $380,847.83. Following the completion of the transaction, the chief executive officer now directly owns 502,188 shares in the company, valued at $70,652,829.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Eric Benevich sold 75,000 shares of the company's stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $139.38, for a total transaction of $10,453,500.00. Following the completion of the transaction, the insider now owns 40,778 shares of the company's stock, valued at $5,683,637.64. The disclosure for this sale can be found here. Insiders sold a total of 186,994 shares of company stock worth $25,806,409 over the last ninety days. 4.40% of the stock is owned by company insiders.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.